[1]敖 劲,杨孔武,穆茂媛,等.微粒-TACE联合伊马替尼治疗进展期胃肠道间质瘤肝转移临床疗效观察[J].介入放射学杂志,2020,29(08):820-823.
 AO Jin,YANG Kongwu,MU Maoyuan,et al.TACE with gelatin sponge microparticles combined with imatinib for liver metastases from advanced gastrointestinal stromal tumors: clinical observation of curative effect[J].journal interventional radiology,2020,29(08):820-823.
点击复制

微粒-TACE联合伊马替尼治疗进展期胃肠道间质瘤肝转移临床疗效观察()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年08
页码:
820-823
栏目:
临床研究
出版日期:
2020-08-25

文章信息/Info

Title:
TACE with gelatin sponge microparticles combined with imatinib for liver metastases from advanced gastrointestinal stromal tumors: clinical observation of curative effect
作者:
敖 劲 杨孔武 穆茂媛 石明涛 利 峰 蔡 争 杨明镇 石荣书
Author(s):
AO Jin YANG Kongwu MU Maoyuan SHI Mingtao LI Feng CAI Zheng YANG Mingzhen SHI Rongshu.
Department of Interventional Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China
关键词:
【关键词】 肝动脉灌注化疗栓塞 胃肠间质瘤 肝转移瘤 伊马替尼
文献标志码:
A
摘要:
【摘要】 目的 评估应用明胶海绵微粒TACE(GSM-TACE)联合伊马替尼治疗进展期胃肠道间质瘤(GIST)肝转移的临床疗效及安全性 方法 2013年1月—2019年1月收治9例不能外科手术的胃肠道间质瘤肝转移患者,规律服用伊马替尼治疗进展后,选用GSMs-TACE联合伊马替尼治疗,对患者的临床资料,CT随访结果,介入治疗的并发症及预后等情况进行总结和分析。术后采用改良实体瘤评价标准(mRECIST)标准评估疗效,术后每月随访1次。结果 9例GIST肝转移均为接受伊马替尼治疗6~30个月进展的患者,且无外科根治性手术指征;9例患者共接受17次GSM-TACE治疗;根据mRECIST评价标准,完全缓解(CR)4例,部分缓解(PR)5例;中位生存时间(24±4.4)个月;无肝脓肿形成,未发生与介入相关的严重并发症。结论 GMS-TACE联合伊马替尼治疗胃肠道间质瘤肝转移是一种安全的、有效的治疗方法。

参考文献/References:


[1] Tryggvason G, Gislason HG, Magnusson MK, et al. Gastroin-testinal stromal tumors in Iceland, 1990- 2003: the icelandic GIST study, a population- based incidence and pathologic risk stratification study[J]. Int J Cancer, 2005, 117:289- 293.
[2] Shi YN, Li Y, Wang LP, et al. Gastrointestinal stromal tumor(GIST) with liver metastases. An 18- year experience from the GIST cooperation group in North China[J]. Medicine(Baltimore),2017,96:e8240.
[3] Caram MV, Schuetze SM. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options[J]. J Surg Oncol, 2011, 104: 888- 895.
[4] 中国CSCO胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗专家共识(2011年版)[J]. 中华胃肠外科杂志, 2012, 15:301- 307.
[5] Kobayashi K, Gupta S, Trent JC, et al. Hepatic artery chemoem- bolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors[J]. Cancer, 2006, 107: 2833- 2841.
[6] Kobayashi K, Szklaruk J, Trent JC, et al. Hepatic arterial embolization and chemoembolization for imatinib- resistant gastrointestinal stromal tumors[J]. Am J Clin Oncol, 2009, 32:574- 581.
[7] Cao G, Li J, Shen L, et al. Transcatheter arterial chemoem-bolization for gastrointestinal stromal tumors with liver metastases[J]. World J Gastroenterol, 2012, 18: 6134- 6140.
[8] Cao G, Zhu X, Li J, Guo J, et al. A comparative study between Embosphere?誖and conventional transcatheter arterial chemoembo- lization for treatment of unresectable liver metastasis from GIST[J]. Chin J Cancer Res, 2014, 26:124- 131.
[9] Chen YY, Yeh CN, Cheng CT, et al. Sunitinib for taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance[J]. World J Gastroenterol, 2011, 17: 2113- 2119.
[10] Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of gorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID): aninternational,multi- centre,randomised,placebo- controlled,phase 3 trial[J]. Lancet, 2013, 381: 295- 302.
[11] 林钧华,刘鲁明,周振华. 胃肠道间质瘤肝转移介入治疗疗效分析[J]. 介入放射学杂志, 2006, 15:283- 285.
[12] Maluccio MA, Covey AM, Schubert J, et al. Treatment of metastatic sarcoma to the liver with bland embolization[J]. Cancer, 2006, 107: 1617- 1623.
[13] Stampfl S, Bellemann N, Stampfl U, et al. Arterial distribution characteristics of embozene particles and comparison with other spherical embolic agents in the porcine acute embolization model[J]. J Vasc Interv Radiol, 2009, 20: 1597- 1607.

备注/Memo

备注/Memo:
(收稿日期:2019- 07- 01)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2020-08-17